EP1360179A2 - Method for preparing compounds derived from thiazolidinedione, oxazolidinedione or hydantoin - Google Patents
Method for preparing compounds derived from thiazolidinedione, oxazolidinedione or hydantoinInfo
- Publication number
- EP1360179A2 EP1360179A2 EP02704834A EP02704834A EP1360179A2 EP 1360179 A2 EP1360179 A2 EP 1360179A2 EP 02704834 A EP02704834 A EP 02704834A EP 02704834 A EP02704834 A EP 02704834A EP 1360179 A2 EP1360179 A2 EP 1360179A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- pph
- formula
- compound
- formic acid
- transition metal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/44—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
- C07D233/78—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to a new process for the preparation of compounds derived from thiazolidinedione, oxazolidinedione or hydantoin of formula (I) from the following compounds of formula (II):
- - Q represents an oxygen atom, a sulfur atom
- - Ql represents an oxygen atom or a sulfur atom
- Ri and R2 identical or different, represent a hydrogen atom, a C ⁇ o alkyl chain; cycloalkyl, alkylaryl, arylalkyl; said alkyl, cycloalkyl, alkylaryl or arylalkyl groups being optionally substituted by an alkyl, an alkoxy or aryloxy, a halogen, a hydroxy, a sulfino, a sulfonyl, an amino such as NH 2 , NHR 3 , N (R 3 ) 2 , with R3 representing an alkyl, an alkoxy or an alkylcarbonyl.
- the compounds derived from thiazolidinedione, oxazolidinedione or hydantoin of formula (I) are known as synthetic intermediates for the preparation of pharmaceutical active ingredients or as pharmaceutical active ingredients such as, for example, pioglitazone, rosiglitazone , troglitazone, ciglitazone.
- the process according to the invention has the advantages of preparing said compounds of formula (I) by generating few impurities, of obtaining a total conversion rate, of eliminating the use of large quantity of solvent, of being selective and easily isolate the product of formula (I).
- the method according to the present invention therefore makes it possible to reduce the financial costs of industrial production of the compounds of formula (I).
- a subject of the present invention is therefore a process for the preparation of a compound derived from thiazolidinedione, oxazolidinedione or hydantoin of formula (I) from a compound of formula (II) below:
- the catalyst based on transition metal used either in the hydrogen transfer reaction or in the hydrogenation reaction, is chosen from a homogeneous or heterogeneous catalyst.
- transition metal catalysts said to be heterogeneous, supported or not, mention is made of Pt, Pt / C, Pt (0) 2 , Pd, Pd / C, Pd / CaC0 3 , Pd / Si0 2 , Pd / BaC0 3 , Pd (OH) 2 / C, Ir, Ir / C, Ru, Ru / C, Rh, Raney Ni, Fe.
- a secondary solvent is advantageously chosen from water, a hydrocarbon such as hexane, heptane, octane, nonane, decane, benzene, toluene and xylene, an ether such as tetrahydrofuran, dioxane , dimethoxyethane, diisopropyl ether and diethylene glycol dimethyl ether, an ester such as ethyl acetate, butyl acetate and ethyl propionate, a ketone such as acetone, diisopropyl ketone, methylisobutyl ketone, ethyl ethyl ketone and acetyl acetone, an alcohol such as methanol, ethanol, n-propanol, isopropanol, butanol, isobutanol, and meth
- a preferred form of implementation of the process for the preparation of compounds of formula (I) by a hydrogenation reaction according to the invention comprises the treatment of the compound of formula (II), in the presence of formic acid and a catalyst, under the following operating conditions:
- a preferred form of implementation of the process for the preparation of compounds of formula (I) by a hydrogen transfer reaction according to the invention comprises the treatment of the compound of formula (II), in the presence of formic acid and d 'A catalyst, preferably under the following operating conditions:
- reaction time of between 0.5 and 40 hours.
- Example 1 Preparation of the compound; [(ethyl-5-pyridyl-2-) ethoxy-4-] benzyl ⁇ -5-thiazolidine-2,4-dione-2,4 according to a hydrogenation reaction.
- reaction medium is cooled to room temperature (20-25 ° C).
- the catalyst is filtered and rinsed with 60 ml of formic acid.
- the filtrate is concentrated under vacuum at 40 ° C to 40 ml. 80 ml of water and 60 ml of formic acid are added to the concentrate. The pH value of the solution is equal to 0.93. 101 g of a solution of
- the crude product is washed in ethanol as follows.
- the product is dissolved in 172 ml of ethanol, the mixture is refluxed for 30 min, cooled to 10 ° C and the product is filtered.
- Example 2 Preparation of the compound; ⁇ [(ethyl-5-pyridyl-2-) ethoxy-4-1benzyl> -5-thiazolidine-2, 4-dione-2, 4 according to a hydrogen transfer reaction by homogeneous catalysis.
- Example 3 Compound preparation; ⁇ [(ethyl-5-pyridyl-2-) ethoxy-4-lbenzyl> -5-thiazolidine-2,4-dione-2,4 according to a hydrogen transfer reaction by heterogeneous catalysis.
- the solution is heated to reflux for 5 hours.
- the HPLC profile of the reaction medium indicates a transformation rate of 78%.
- the medium is concentrated to 5 ml.
- Example 4 Compound preparation; -f [(ethyl-5-pyridyl-2-) ethoxy-4-1benzyl> -5-thiazolidine-2,4-dione-2,4 according to a hydrogen transfer reaction by heterogeneous catalysis.
- the solution is heated to reflux (105 ° C) for 21 hours.
- the HPLC profile of the reaction medium indicates a conversion rate of 66%.
- the medium is concentrated to 5 ml.
- Example 5 Preparation of the compound: -ff (ethyl-5-pyridyl-2-) ethoxy-4-] benzyl> -5-thiazolidine-2, 4-dione-2, 4 according to a hydrogen transfer reaction by heterogeneous catalysis. Under nitrogen, in a 0.5 1 flask are introduced 20 g of ⁇ [(ethyl-5-pyridyl-2-) ethoxy-4-] benzylylidene ⁇ -5-thiazolidine-2, 4-dione-2, 4, 0.6 g of Pt (0) 2 (2.5% platinum / substrate) and 200 ml of 99% formic acid. The solution is heated to the temperature of 84
- the HPLC profile of the reaction medium indicates a conversion rate of 98.3% into the product formed.
- reaction medium is filtered and the filtrate is concentrated to 40 ml.
- the product is filtered.
- the product is purified by repasting in ethanol.
- the solution is heated to the temperature of 80-85 ° C for 19 hours 30 minutes.
- the HPLC profile of the reaction medium indicates a conversion rate of 98.4% into the product formed.
- Example 7 Preparation of the compound: -f [(ethyl-5-pyridyl-2-) ethoxy-4-1benzyl> -5-thiazolidine-2,4-dione-2,4 according to a hydrogen transfer reaction by heterogeneous catalysis. Under nitrogen, in a 100 ml tetracol are introduced 5 g of ⁇ [(ethyl-5-pyridyl-2-) ethoxy-4-] benzylylidene ⁇ -5-thiazolidine-2, 4-dione-2, 4, 0.203 g of Pt (0) 2 (3.4% platinum / substrate) and 50 ml of 99% formic acid. The solution is heated to the temperature of 80-
- the HPLC profile of the reaction medium indicates a conversion rate of 98% into the product formed.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0102010A FR2820741A1 (en) | 2001-02-14 | 2001-02-14 | Pure 5-alkyl-thiazolidinedione, oxazolidinedione or hydantoin derivative preparation, for use as drug or intermediate, by reduction of corresponding alkylidene compound using formic acid |
FR0102010 | 2001-02-14 | ||
FR0105206 | 2001-04-17 | ||
FR0105206A FR2820742B1 (en) | 2001-02-14 | 2001-04-17 | PROCESS FOR THE PREPARATION OF COMPOUNDS DERIVED FROM THIAZOLIDINEDIONE, OXAZOLIDINEDIONE OR HYDANTOIN |
PCT/FR2002/000571 WO2002064577A2 (en) | 2001-02-14 | 2002-02-14 | Method for preparing compounds derived from thiazolidinedione, oxazolidinedione |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1360179A2 true EP1360179A2 (en) | 2003-11-12 |
Family
ID=26212876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02704834A Withdrawn EP1360179A2 (en) | 2001-02-14 | 2002-02-14 | Method for preparing compounds derived from thiazolidinedione, oxazolidinedione or hydantoin |
Country Status (13)
Country | Link |
---|---|
US (1) | US6849741B2 (en) |
EP (1) | EP1360179A2 (en) |
JP (1) | JP2004520401A (en) |
KR (1) | KR100856140B1 (en) |
CN (1) | CN1491218A (en) |
AU (1) | AU2002238645A1 (en) |
BR (1) | BR0206967A (en) |
CA (1) | CA2438105A1 (en) |
FR (1) | FR2820742B1 (en) |
IL (1) | IL157101A0 (en) |
MX (1) | MXPA03007263A (en) |
RU (1) | RU2003127720A (en) |
WO (1) | WO2002064577A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003053367A2 (en) * | 2001-12-20 | 2003-07-03 | Teva Pharmaceutical Industries Ltd. | Hydrogenation of precursors to thiazolidinedione antihyperglycemics |
CZ297347B6 (en) * | 2004-09-21 | 2006-11-15 | Zentiva, A. S. | Process for preparing rosiglitazone |
EP1903042A3 (en) * | 2006-09-22 | 2008-05-28 | Cadila Pharmaceuticals Limited | An improved process for hydrogenation of 5-(substituted Benzylidene) 2,4- Thiazolidine Dione compounds to give corresponding ( +/- ) 5- (substituted Benzyl ) 2,4-Thiazolidine Dione |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4812570A (en) * | 1986-07-24 | 1989-03-14 | Takeda Chemical Industries, Ltd. | Method for producing thiazolidinedione derivatives |
EP0839812A1 (en) * | 1990-04-27 | 1998-05-06 | Sankyo Company Limited | Preparation of benzylthiazolidine derivatives |
AU3231093A (en) * | 1991-12-20 | 1993-07-28 | Upjohn Company, The | A reduction method for substituted 5-methylene-thiazolidinediones |
JP3163361B2 (en) * | 1992-03-12 | 2001-05-08 | 味の素株式会社 | Method for producing 5-alkylhydantoin derivative |
US5399632A (en) * | 1992-09-30 | 1995-03-21 | Exxon Research & Engineering Co. | Hydrogenation process for unsaturated homo and copolymers |
JPH06199808A (en) * | 1993-01-04 | 1994-07-19 | Ajinomoto Co Inc | Production of 5-cyclohexylmethylhydantoin derivative and intermediate for production thereof |
JPH08277279A (en) * | 1995-04-05 | 1996-10-22 | Nitto Chem Ind Co Ltd | Production of benzylthiazolidindione derivative |
US5952509A (en) * | 1996-06-27 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Production of benzaldehyde compounds |
UY24886A1 (en) * | 1997-02-18 | 2001-08-27 | Smithkline Beecham Plc | TIAZOLIDINDIONA |
DE19711616A1 (en) * | 1997-03-20 | 1998-09-24 | Boehringer Mannheim Gmbh | Improved process for the preparation of thiazolidinediones |
JP4084501B2 (en) * | 1999-07-01 | 2008-04-30 | 三井化学株式会社 | α-Mercaptocarboxylic acid and process for producing the same |
-
2001
- 2001-04-17 FR FR0105206A patent/FR2820742B1/en not_active Expired - Fee Related
-
2002
- 2002-02-14 JP JP2002564510A patent/JP2004520401A/en active Pending
- 2002-02-14 KR KR1020037010672A patent/KR100856140B1/en not_active IP Right Cessation
- 2002-02-14 AU AU2002238645A patent/AU2002238645A1/en not_active Abandoned
- 2002-02-14 EP EP02704834A patent/EP1360179A2/en not_active Withdrawn
- 2002-02-14 CA CA002438105A patent/CA2438105A1/en not_active Abandoned
- 2002-02-14 CN CNA028049691A patent/CN1491218A/en active Pending
- 2002-02-14 MX MXPA03007263A patent/MXPA03007263A/en unknown
- 2002-02-14 RU RU2003127720/04A patent/RU2003127720A/en not_active Application Discontinuation
- 2002-02-14 WO PCT/FR2002/000571 patent/WO2002064577A2/en active Application Filing
- 2002-02-14 BR BR0206967-9A patent/BR0206967A/en not_active IP Right Cessation
- 2002-02-14 IL IL15710102A patent/IL157101A0/en unknown
-
2003
- 2003-08-07 US US10/636,155 patent/US6849741B2/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
See references of WO02064577A2 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002238645A1 (en) | 2002-08-28 |
KR20030082594A (en) | 2003-10-22 |
FR2820742A1 (en) | 2002-08-16 |
US20040059121A1 (en) | 2004-03-25 |
CN1491218A (en) | 2004-04-21 |
IL157101A0 (en) | 2004-02-08 |
CA2438105A1 (en) | 2002-08-22 |
BR0206967A (en) | 2004-03-09 |
WO2002064577A2 (en) | 2002-08-22 |
WO2002064577A3 (en) | 2003-01-03 |
JP2004520401A (en) | 2004-07-08 |
US6849741B2 (en) | 2005-02-01 |
KR100856140B1 (en) | 2008-09-03 |
FR2820742B1 (en) | 2005-03-11 |
RU2003127720A (en) | 2005-03-20 |
MXPA03007263A (en) | 2005-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1926102B (en) | Process for preparing N-protected 4-ketoproline derivatives | |
EP2042497B1 (en) | Method for producing strontium ranelate and its hydrates | |
EP1907396B1 (en) | Method for preparing 4 -amino-4'-demethyl-4-desoxypodophyllotoxin | |
CH679150A5 (en) | ||
EP1360179A2 (en) | Method for preparing compounds derived from thiazolidinedione, oxazolidinedione or hydantoin | |
JPS6045621B2 (en) | Method for producing butanone derivatives | |
JPH10509177A (en) | Method for producing 5-hydroxymethylthiazole | |
EP0069002A1 (en) | Process for the preparation of (thienyl-2)-2 ethyl amines and (thienyl-3)-2 ethyl amines | |
FR2820741A1 (en) | Pure 5-alkyl-thiazolidinedione, oxazolidinedione or hydantoin derivative preparation, for use as drug or intermediate, by reduction of corresponding alkylidene compound using formic acid | |
WO2008135386A1 (en) | Chiral ligands of the n-heterocyclic carbene type for asymmetrical catalysis | |
JP3870647B2 (en) | Process for producing optically active α-hydroxy ketones | |
CA1312625C (en) | Process for the preparation of aromatic aldehydes | |
WO1996038447A1 (en) | 2-azabicyclo[2.2.1]heptane derivatives, preparation and application thereof | |
EP0452168A1 (en) | Process for the preparation of N-phenyl benzoquinone-imine | |
FR2686876A1 (en) | PROCESS FOR THE PREPARATION OF ARYLACETIC ACIDS AND THEIR SALTS OF ALKALI METALS. | |
CH643226A5 (en) | PROCESS FOR THE MANUFACTURE OF CARBONYL COMPOUNDS BY OXIDATION OF OLEFINIC COMPOUNDS. | |
EP0931059B1 (en) | Method for preparing a cyanobiphenyl | |
WO2005030719A1 (en) | Novel method for preparing cis-octahydro-isoindole | |
EP0828740B1 (en) | 2-azabicyclo[2.2.1]heptane derivatives, preparation and application thereof | |
FR2947263A1 (en) | PROCESS FOR CATALYZING HYDROGEN TRANSFER REACTIONS | |
WO2005030718A1 (en) | Novel method of preparing cis-octahydro-isoindole | |
FR2687668A1 (en) | Process for the preparation of alkylaromatic diamines, new diimines and diamines and use of the diamines obtained for the manufacture of polyamides | |
WO1999040060A1 (en) | Method for hydrogenating 5-nitrosalicylic acids | |
FR2642426A1 (en) | ORGANOGERMANIUM COMPOUND, PROCESSES FOR THEIR MANUFACTURE, AND INHIBITOR AGENT OF OPIOID PEPTIDE DEGRADATION ENZYMES | |
WO1999006392A1 (en) | Method for preparing 2h-1 benzopyranes and synthesis intermediates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030822 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
17Q | First examination report despatched |
Effective date: 20040305 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: PINTUS, TONY Inventor name: DERRIEN, YVON Inventor name: BULLIARD, MICHEL,SYNKEM FOURNIER PHARMA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090901 |